Nuvectis Pharma, Inc.(NVCT)

Biotechnology · Fort Lee, NJ

$20.05-1.34 (-6.26%)

Delayed quote: Oct 6, 2026, 3:09 PM EDT

Price/FCF Ratio: N/A

Basis: FMP quote market capitalization / four-quarter operating cash flow less absolute capital expenditures. Source: stored company filings and market data; unavailable inputs remain N/A.

The Price/FCF ratio is N/A as of 2026-10-06T19:12:57.104Z.

Stored calculation inputs

Calculation as of: 2026-10-06T19:12:57.104Z.

Quote observation: 2026-10-06T19:09:57.000Z. Amounts in USD. The price header may show a later quote.

Quote market capitalization: 532,055,401
TTM free cash flow · period ending 2026-06-30: -19,510,000

FMP input reference: b447d722f006e82d19b5d98ef6acffd249f934693947ae19b5e437b2b2585766

P/E Ratio|FCF Growth|Operating Margin|All Metrics

Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.

NVCT Price/FCF Ratio Metrics

PRICE/FCF RATIO

N/A

NVCT Competitors' Price/FCF Ratio

NVCT

Nuvectis Pharma, Inc.

Current

Market Cap

$532.06M

Price/FCF Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

PROK

ProKidney Corp.

vs NVCT

Market Cap

$534.37M

Price/FCF Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

DCTH

Delcath Systems, Inc.

vs NVCT

Market Cap

$532.25M

Price/FCF Ratio

30.40

TTM Avg

34.94

3Y Avg

46.00

5Y Avg

46.00

PHAT

Phathom Pharmaceuticals, Inc.

vs NVCT

Market Cap

$543.16M

Price/FCF Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

IMMX

Immix Biopharma, Inc.

vs NVCT

Market Cap

$524.29M

Price/FCF Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

MNPR

Monopar Therapeutics Inc.

vs NVCT

Market Cap

$542.62M

Price/FCF Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

STTK

Shattuck Labs, Inc.

vs NVCT

Market Cap

$546.10M

Price/FCF Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

BLSM

BlossomHill Therapeutics, Inc.

vs NVCT

Market Cap

$521.72M

Price/FCF Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

ALT

Altimmune, Inc.

vs NVCT

Market Cap

$520.37M

Price/FCF Ratio

N/A

TTM Avg

0.26

3Y Avg

0.26

5Y Avg

0.26

ACRS

Aclaris Therapeutics, Inc.

vs NVCT

Market Cap

$514.66M

Price/FCF Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

NAME	MARKET CAP	PRICE/FCF RATIO	TTM	3Y	5Y
Nuvectis Pharma, Inc. (NVCT)	$532.06M	N/A	N/A	N/A	N/A
ProKidney Corp. (PROK)vs ›	$534.37M	N/A	N/A	N/A	N/A
Delcath Systems, Inc. (DCTH)vs ›	$532.25M	30.40	34.94	46.00	46.00
Phathom Pharmaceuticals, Inc. (PHAT)vs ›	$543.16M	N/A	N/A	N/A	N/A
Immix Biopharma, Inc. (IMMX)vs ›	$524.29M	N/A	N/A	N/A	N/A
Monopar Therapeutics Inc. (MNPR)vs ›	$542.62M	N/A	N/A	N/A	N/A
Shattuck Labs, Inc. (STTK)vs ›	$546.10M	N/A	N/A	N/A	N/A
BlossomHill Therapeutics, Inc. (BLSM)vs ›	$521.72M	N/A	N/A	N/A	N/A
Altimmune, Inc. (ALT)vs ›	$520.37M	N/A	0.26	0.26	0.26
Aclaris Therapeutics, Inc. (ACRS)vs ›	$514.66M	N/A	N/A	N/A	N/A

Free Cash Flow Valuation

P/FCF Ratio

N/A

FCF Yield

N/A

Price/FCF Ratio Formula & Definition

P/FCF measures market price relative to free cash flow per share. Free cash flow is operating cash flow after capital expenditures.

Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute

Price/FCF Ratio: N/A

NVCT Price/FCF Ratio Metrics

NVCT Competitors' Price/FCF Ratio

Free Cash Flow Valuation

Price/FCF Ratio Formula & Definition

Related Metrics